Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 1997

View Archived Issues

MMP inhibitors synthesized by Otsuka

Japanese researchers describe anticoagulants

Taisho discloses promoters of NGF production

Selectin inhibitors from TBC

Selective nAChR ligands prepared by Novo Nordisk

Cytotoxic colchicine derivatives from Indena

Pfizer's new antifungal agents

Harvard College discloses vascular injury-associated gene

ArQule reports financial results for fourth quarter and year ended December 31, 1996

Cephalon announces 1996 financial results

Enzon reports second-quarter results

The Liposome Company reports fourth-quarter and 1996 results

Vion Pharmaceuticals reports fourth-quarter and year-end financial results

Mediator release inhibitors described by French investigators

Candidate proton pump inhibitor described by Dainippon

GSH deficiency linked to impaired survival in HIV/AIDS

Positive clinical results for inhaled indomethacin

Cell Genesys expands trials of AIDS gene therapy

Glaxo Wellcome evaluates ondansetron alone and in combination for emesis

Medicis acquires topical steroids

Positive results reported for VasoCare in MI

Axcan H. pylori trial nearing completion

AEterna codevelopment agreement for AE-941

Optivax phase I results reported at AAAI/AAI/CIS meeting

PathoGenesis to seek approval for tobramycin

Italian researchers report effective combination therapy for HIV-associated NHL

IND filed for SunPharm IBD treatment

Riluzole now available in France

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...